New stock news | Deit Medicine's Hong Kong Stock IPO prospectus has become invalid.

DeMei Pharmaceuticals Co., Ltd. (DeMei Pharmaceuticals for short) submitted its Hong Kong IPO prospectus on October 30, 2025 for a period of 6 months, which expired on April 30, 2026. Huatai International was the sole sponsor at the time of submission. The prospectus shows that DeMei Pharmaceuticals is an innovative pharmaceutical company that specializes in skin health. It operates in an integrated manner around the research, production, and sales of prescription drugs and dermatological skincare products, aiming to provide comprehensive solutions for skin health from prevention, treatment to long-term care. The company has built a rich and diversified product portfolio that covers major skin diseases with significant unmet clinical needs. According to the ZOZHI consultation report, among innovative drug companies in China, the company ranks first in the number of indications covered by its skin disease products, and in 2024, the company's revenue from prescription dermatological drugs also ranked first.